Alert detail
LCD L39583: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — Palmetto GBA
What changed
Palmetto GBA covers molecular biomarker testing for cSCC risk stratification.
Who’s affected: Dermatology billing teams · Effective: August 18, 2024
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 10 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.